Status:

COMPLETED

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Lead Sponsor:

GlaxoSmithKline

Conditions:

Hepatitis B

Eligibility:

All Genders

18-40 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following...

Detailed Description

At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham

Eligibility Criteria

Inclusion

  • Between 18 and 40 years old.
  • Written informed consent will have been obtained from the subjects.
  • Good physical condition as established by physical examination and history taking at the time of entry.
  • Female participants will avoid becoming pregnant during the study period and they will have been on a contraceptive program for at least 2 months before entry

Exclusion

  • Pregnancy or lactation.
  • Serological signs of HBV infection
  • Elevated serum liver enzymes
  • Any vaccination against hepatitis B in the past.
  • Any previous administration of MPL.
  • History of significant and persisting hematologic, hepatic, renal, cardiac or respiratory disease.
  • Axillary temperature \> 37.5°C at the time of injection.
  • Any acute disease at the moment of entry.
  • Chronic alcohol consumption.
  • Any treatment with immunosuppressive or immunostimulant therapy.
  • Any chronic drug treatment, which in the investigator's opinion, precludes inclusion into the study.
  • History of allergic disease likely to be stimulated by any component of the vaccine.
  • Administration of any other vaccine(s) or any immunoglobulin during the study period.
  • Simultaneous participation in any other clinical trial.

Key Trial Info

Start Date :

June 1 1993

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 1994

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00697125

Start Date

June 1 1993

End Date

July 1 1994

Last Update

June 13 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

GSK Clinical Trials Call Center

Ghent, Belgium